Monopar's ALXN1840 Receives FDA Rare Pediatric Disease Designation
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Monopar Therapeutics secured Rare Pediatric Disease designation from the FDA for its lead candidate ALXN1840, enhancing its value with the potential for a Priority Review Voucher upon approval.
Key Events · Product Development and Regulatory · MNPR
-
FDA Grants Rare Pediatric Disease Designation
ALXN1840 (tiomolibdate choline) for Wilson disease received Rare Pediatric Disease (RPD) designation from the FDA.
-
Potential for Priority Review Voucher
The RPD designation provides the potential to receive a valuable pediatric Priority Review Voucher (PRV) upon NDA approval, which can be sold or used to expedite future drug reviews.
-
Builds on Positive Clinical Data
This regulatory milestone follows a series of positive Phase 2 and Phase 3 clinical data announcements for ALXN1840, reinforcing its development path towards a mid-2026 NDA submission.
Analysis · MNPR · Life Sciences
The FDA's Rare Pediatric Disease designation for ALXN1840 is a significant regulatory milestone. It creates the potential for Monopar to receive a valuable Priority Review Voucher (PRV) upon NDA approval, which can either be sold for substantial cash or used to expedite the review of another drug. This designation further de-risks the development and commercialization path for their lead candidate, ALXN1840, which has already shown highly positive Phase 3 data for Wilson disease.
At the time of this filing, MNPR was trading at $94.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $633.5M. The 52-week trading range was $29.18 to $105.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.